Bero, Lisa - University of Sydney

研究领域

Professor Bero’s overall research program addresses the broad questions regarding research evidence including: What is evidence? How can we reduce bias in the evidence base, specifically the design, conduct and reporting of research? How can we communicate research findings in an understandable and convincing way to a variety of stakeholders? How can we promote the use of evidence in decision making while taking into account the social, political and ethical context of decisions? Her planned current and future work includes methodological analyses of nutrition research relevant to the treatment and prevention of obesity, diabetes and cardiovascular disease and promoting the use of quality evidence to inform health policy to reduce the burden of these diseases. Her research program will focus on describing cultural, social, corporate, political and other influences on the design, conduct and publication of research. An additional program will focus on improving medicines use for noncommunicable diseases in low-resource settings. Her team will study the process of innovation for medicines for noncommunicable disease, assess barriers and facilitators to the quality use of essential medicines, and develop and test interventions to improve essential medicines policy, supply, distribution and use. Further proposed research includes analyses of the results and biases in preclinical animal studies, as these studies are critical for evaluating the efficacy and safety of drugs before proceeding to human testing. The aim is to provide an internationally-applicable evidence base for developing strategies and policies for controlling bias in preclinical animal research. Future research will explore ways to improve the assessment of the risk of bias in clinical trials of high-cost new cancer therapeutics, and studies on the impact of unpublished data on the cost-effectiveness of medicines.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Alexander, P., Gionfriddo, M., Li, S., Bero, L., Stoltzfus, R., Neumann, I., Brito, J., Djulbegovic, B., Montori, V., Norris, S., et al (2016). A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 70, 111-122. [More Information] Apollonio, D., Bero, L. (2016). Challenges to generating evidence-informed policy and the role of systematic reviews and (perceived) conflicts of interest. Journal of Communication in Healthcare, 9(2), 135-141. [More Information] Wang, Z., Norris, S., Bero, L. (2016). Implementation plans included in World Health Organisation guidelines. Implementation Science, 11(1), 1-9. [More Information] Grundy, Q., Bero, L., Malone, R. (2016). Marketing and the Most Trusted Profession: The Invisible Interactions Between Registered Nurses and Industry. Annals of Internal Medicine, 164(11), 733-739. [More Information] Apollonio, D., Bero, L., Wolfe, N. (2016). Realist review of policy intervention studies aimed at reducing exposures to environmental hazards in the United States. BMC Public Health, 16(1), 1-15. [More Information] Bero, L., Anglemyer, A., Vesterinen, H., Krauth, D. (2016). The relationship between study sponsorship, risks of bias, and research outcomes in atrazine exposure studies conducted in non-human animals: Systematic review and meta-analysis. Environment International, 92-93, 597-604. [More Information] Alexander, P., Brito, J., Neumann, I., Gionfriddo, M., Bero, L., Djulbegovic, B., Stoltzfus, R., Montori, V., Norris, S., Schunemann, H., et al (2016). World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 72, 98-106. [More Information] Chiu, Y., Bero, L., Hessol, N., Lexchin, J., Harrington, C. (2015). A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy, 119(6), 802-813. [More Information] Tran, D., Bero, L. (2015). Barriers and facilitators to the quality use of essential medicines for maternal health in low-resource countries: An Ishikawa framework. Journal of Global Health, 5(1), 1-9. [More Information] Tuller, D., Bero, L. (2015). Big Tobacco and Drugstore Chains: A Long, Cozy Relationship. JAMA Oncology, 1(9), 1215-1216. [More Information] Hill, S., Bero, L., McColl, G., Roughead, E. (2015). Expensive medicines: ensuring objective appraisal and equitable access. Bulletin of the World Health Organization, 93(1), 4-4A. [More Information] Anglemyer, A., Krauth, D., Bero, L. (2015). Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: A meta-analysis. BMC Medical Research Methodology, 15(1), 1-10. [More Information] Elliott, J., Grimshaw, J., Altman, R., Bero, L., Goodman, S., Henry, D., Macleod, M., Tovey, D., Tugwell, P., White, H., et al (2015). Informatics: Make sense of health data. Nature, 527(7576), 31-32. [More Information] Siler, K., Lee, K., Bero, L. (2015). Measuring the effectiveness of scientific gatekeeping. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(2), 360-365. [More Information] Moynihan, R., Nickel, B., Hersch, J., Beller, E., Doust, J., Compton, S., Barratt, A., Bero, L., McCaffery, K. (2015). Public Opinions about Overdiagnosis: A National Community Survey. PloS One, 10(5), 1-13. [More Information] Bero, L., Siler, K., Lee, K. (2015). Reply to Margalida and Colomer: Science should strive to prevent mistakes, not corrections. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(13), E1512-E1512. [More Information] Chang, L., Dhruva, S., Chu, J., Bero, L., Redberg, R. (2015). Selective reporting in trials of high risk cardiovascular devices: Cross sectional comparison between premarket approval summaries and published reports. BMJ, 350, 1-7. [More Information] Mahady, S., Schlub, T., Bero, L., Moher, D., Tovey, D., George, J., Craig, J. (2015). Side effects are incompletely reported among systematic reviews in gastroenterology. Journal of Clinical Epidemiology, 68(2), 144-153. [More Information] Schroll, J., Abdel-Sattar, M., Bero, L. (2015). The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. Journal of Clinical Epidemiology, 68(1), 102-107. [More Information] Abdel-Sattar, M., Krauth, D., Anglemyer, A., Bero, L. (2015). The relationship between risk of bias criteria, research outcomes, and study sponsorship in a cohort of preclinical thiazolidinedione animal studies: a meta-analysis. Evidence-based Preclinical Medicine, 1(1), 11-20. [More Information]